Condition: Solid Tumor, Unspecified, Adult · Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
The objective of STING study is to perform high throughput molecular analysis (next generation sequencing +/- immunological profiling) to estimate the proportion of patients with cancer presenting at least one targetable genomic alteration.
This description comes directly from the study's public registry record.
Antoine Italiano, MD PhD · +33 (0)1 42 11 42 11 · antoine.italiano@gustaveroussy.fr
Clementine MAHAUT · +33 (0)1 42 11 23 34 · clementine.mahaut@gustaveroussy.fr
Always discuss trial participation with your own doctor first.
| Gustave Roussy Cancer Campus Grand Paris | Villejuif, Val de Marne, France | Recruiting |
| Hôpital Marie-Lannelongue | Le Plessis-Robinson, France | Recruiting |
| Hôpital Saint-Joseph | Paris, France | Not Yet Recruiting |
| Hôpital Foch | Suresnes, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04932525